V3-RGN-09 Molecular Simulator: A Formally Verified Ada/SPARK In Silico Engine for Dual-Target Retinal Regeneration and Biophysical Blind-Test Validation
Year: 2026
Type: software
Abstract: BACKGROUND & PURPOSE: Retinal degenerative disorders—such as age-related macular degeneration (AMD), diabetic macular edema (DME), and glaucoma—represent complex multi-layered neuropathologies that remain challenging to model in silico without computational instability or artificial bias. Traditional computational biology frameworks (primarily C/C++ or Python) lack formal safety guarantees and deterministic physical boundaries. This work introduces the "V3-RGN-09 Molecular Simulator", an in silico biophysical platform developed entirely in Ada/SPARK 2022 to simulate the complete mechanics of multi-layered retinal regeneration and drug-target interactions with 100% formal mathematical proof (zero runtime exceptions, zero memory bugs). METHODOLOGY & ARCHITECTURE: The simulator relies on four locked V3 Invariants: 1. Physical Mass/Pressure Invariant (Ψ_V3 = 48,016.8 kg·m⁻²), 2. Critical Biophysical Phase Lock Attractor (Φ_critical = -51.10 mV vs. Φ_basal = -70.00 mV), 3. Heptadic Layer Closure (k = 7, modeling all 7 distinct anatomical retinal layers), 4. Modulo-9 Checksum Predicates guaranteeing structural integrity across all execution threads. The core module evaluates the novel synthetic hybrid molecule V3-RGN-09 (Molecular Weight: 842.6 Da, ΔG = -11.8 kcal/mol, Kd = 0.042 nM), engineered from 3D atomic coordinates of PDB 6M76 (TGFBR1 / Anti-TGF-β Domain A) and PDB 1BND (TrkB/PEDF Neurotrophic Domain B). EXPERIMENTAL VALIDATION & BLIND TESTS: The architecture underwent extensive stress-testing and empirical validation: 1. Blind Diagnostic Simulations (16/16 Successful): Without diagnostic tags or clinical labels, the engine evaluated raw physical parameters (fluid pressure, ion gradients, mechanical stress, enzymatic clearance). Through differential integration across the 7 layers (k=7), the engine autonomously rediscovered exact real-world pathological footprints, including Wet/Dry AMD, Glaucoma, Stargardt Disease, Central Retinal Artery Occlusion (CRAO), Macular Holes, and CAR Retinopathy with 100% concordance to clinical benchmarks. 2. Reverse Engineering / Back-Propagation Test: By setting an optimal clinical recovery target (Phase Lock at -51.10 mV in 18 days with >75% fibrosis reduction), back-propagation equations independently generated the precise structural and affinity constraints of the V3-RGN-09 hybrid pharmacophore. 3. Extreme Stress Testing & Fuzzing: Monte-Carlo simulations (100,000 runs under ±15% parameter noise) demonstrated a 99.98% convergence rate to the Φ_critical attractor. Simulated memory corruption and bit-flips triggered instantaneous execution isolation (0.00 ms crash rate) via SPARK pre/post-conditions. 4. Clinical Benchmark Cross-Validation: Predicted clinical outcomes (+16.4 ETDRS letters gain, 78% fibrosis reduction, 92% RPE preservation) were cross-validated against real-world trial datasets from ANCHOR (n=423) and MARINA (n=716). CONCLUSION: The V3-RGN-09 Molecular Simulator bridges high-integrity critical software engineering (DO-178C standards) with computational biophysics. It provides a proven, deterministic, and formally verified foundation for in silico drug discovery, ready for TRL 4 in vitro and in vivo translational research.
Author: benhadid, outail
Language: English
Subfield: Ophthalmology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7171699972